Seelos Therapeutics Company Overview
About Seelos Therapeutics
Seelos Therapeutics (NASDAQ:SEEL) is a biopharmaceutical company deeply engaged in the development of therapies addressing unmet needs in central nervous system (CNS) disorders and rare diseases. Their dynamic pipeline includes projects targeting conditions such as amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), Parkinson's disease, and other profound medical challenges. Seelos Therapeutics is committed to innovative research and development, aiming to bring groundbreaking treatments to patients who currently have limited or no therapeutic options. Through a focused and patient-centric approach, their objective is to revolutionize the treatment landscape for these serious conditions and improve the quality of life for patients and their families worldwide.
Snapshot
Operations
Produtos e/ou serviços de Seelos Therapeutics
- SLS-002 is an intranasal ketamine treatment aimed at addressing acute suicidal ideation and behavior in major depressive disorder.
- SLS-005 (trehalose) targets neurodegenerative disorders like ALS and Sanfilippo syndrome, showing promise in slowing disease progression.
- SLS-006 is a partial dopamine agonist for Parkinson's disease, potentially offering a novel approach to managing motor symptoms without the side effects of current treatments.
- SLS-008 is being developed for an undisclosed rare pediatric disease, focusing on a novel therapeutic pathway.
- SLS-007 is a peptide-based therapy aimed at inhibiting alpha-synuclein aggregation, a key factor in Parkinson's disease progression.
- SLS-004 employs an epigenetic modification strategy to target Parkinson's disease by demethylating SNCA promoter, possibly reducing alpha-synuclein production.
equipe executiva do Seelos Therapeutics
- Dr. Raj Mehra J.D., Ph.D.CEO, Founder, President & Chairman
- Mr. Michael J. GolembiewskiChief Financial Officer
- Mr. Anthony MarcianoChief Communications Officer
- Mr. Gopal Krishna Ph.D.Head of Manufacturing & Technical Operations
- Tim Whitaker M.D.Chief Medical Officer
- Ms. Karen FusaroSenior VP & Head of Clinical Operations